جستجوی استاد راهنمای دانشگاهی

برای مسیر پژوهشی‌تان، استاد راهنما، استاد دانشگاه و پژوهشگر مناسب را پیدا کنید و با آن‌ها ارتباط بگیرید.

نمایش ۷۳۶-۷۵۰ از ۲۲٬۱۲۴ استاد راهنما

اطلاعات پروفایل‌ها از صفحات عمومی دانشگاه‌ها گرفته شده و ممکن است به‌روز نباشد.

Remy Robertمشاهده پروفایل

دانشیار

Monash UniversityAustralia

Remy Robert is an Associate Professor in Physiology at Monash University, affiliated with the Monash Biomedicine Discovery Institute. His primary role is in the Department of Molecular Biology and Biochemistry, focusing on therapeutic antibody development and antibody engineering. He holds a PhD from the University of Bordeaux and completed a postdoctoral fellowship at CSIRO, followed by a research fellowship at Monash University under Professor Charles Mackay. Dr. Robert’s research spans translational medicine, aiming to convert academic discoveries into antibody therapies. His expertise includes protein engineering, autoimmune disease mechanisms, and inflammation modulation. Key projects include the development of bispecific antibodies for cancer immunotherapy, chemokine-targeted therapeutics, and preclinical studies on CCR6-mediated autoimmune diseases. His research outputs emphasize antibody engineering techniques, mouse models of atopic dermatitis, and the role of receptors like GPR109A and CXCR1 in immune regulation. Collaborations involve institutions like CSIRO and global networks in immunology. He leads grants on cancer immunotherapy and has contributed to patents related to antibody technologies. Dr. Robert’s work aligns with UN Sustainable Development Goals focused on good health and well-being. His lab actively pursues innovations in therapeutic antibodies, with a focus on translational applications in oncology and autoimmune diseases.

پروفایل رسمی دانشگاه

Ong Yong Szeمشاهده پروفایل

مدرس

Monash UniversityAustralia

Dr. Ong Yong Sze is a Lecturer at Monash University Malaysia’s School of Pharmacy, specializing in precision oncology and nanomedicine. She holds a PhD in Pharmacology (2019) and a Bachelor of Biomedical Science (2013), both from Universiti Putra Malaysia. Her research focuses on cancer nanomedicine, natural product-based therapeutics, and environmental health risk assessment, with a commitment to developing low-toxicity therapies and addressing environmental pollutants’ health impacts. She has received prestigious awards, including the PeerJ Award for Best Poster (2021) and Oral Presentation Award (2025). Education: PhD in Pharmacology, Universiti Putra Malaysia (2019) Bachelor of Biomedical Science, Universiti Putra Malaysia (2013) Research Interests: Her work bridges nanotechnology, natural pharmacology, and toxicity studies. Key areas include engineering targeted nanoparticle drug delivery systems, exploring plant-derived anticancer compounds, and evaluating environmental pollutants like microplastics. Her interdisciplinary approach aims to enhance therapy precision while ensuring patient safety. Grants & Projects: She leads and collaborates on projects such as Development of a 3D Metastatic Breast Cancer-on-Chip Model (2023–2025) and Engkabang as High-Quality Cosmeceuticals (2023–2026), focusing on drug delivery, gut health, and functional foods. Lab & Teams: Her lab integrates nanomedicine and environmental toxicology, with collaborations spanning Malaysia, Portugal, and Taiwan. She actively organizes workshops on cell culture and drug discovery, furthering academic engagement.

پروفایل رسمی دانشگاه

Sam Butterworthمشاهده پروفایل

استاد

The University of ManchesterUnited Kingdom

Sam Butterworth is a Professor of Medicinal Chemistry at the University of Manchester, holding the Chair in Medicinal Chemistry. Previously, he worked at the University of Birmingham (2013-2016) and AstraZeneca (2005-2013), where his research contributed to the development of osimertinib (Tagrisso), an FDA-approved anti-cancer drug targeting EGFR mutations. He leads the Butterworth Group, focusing on synthetic and biological chemistry to address human health challenges, particularly cancer therapy and drug delivery systems. Education & Experience: Senior Lecturer at Manchester (2016-2024), AstraZeneca R&D (2005-2013), Birmingham academic role (2013-2016) Key Projects: ERK5 inhibitors for breast cancer, nanoparticle drug delivery, and HDX mass spectrometry for protein dynamics Research Interests: Medicinal chemistry, synthetic organic methods, targeted cancer therapies, nanoparticle systems, and enzyme modulators (e.g., NAMPT). His group collaborates closely with clinicians and biomedical researchers to validate compounds in disease models. Publications: Over 25 peer-reviewed articles in journals like Angewandte Chemie and Acta Pharmaceutica Sinica B , focusing on catalytic methods, drug design, and nanotechnology. Awards: 2017 RSC Malcolm Campbell Award, 2018 ACS Heroes of Chemistry Award Grants/Leadership: Co-Investigator on projects totaling £[X] funding, including EPSRC and Wellcome Trust grants Labs & Teams: Active in Manchester’s Institute of Inflammation and Repair and collaborates with the Christie NHS Foundation Trust for translational cancer research.

پروفایل رسمی دانشگاه

Jian Luمشاهده پروفایل

استاد

The University of ManchesterUnited Kingdom

Jian Lu is a Professor in the Department of Biological Physics at The University of Manchester, affiliated with the Christabel Pankhurst Institute. He holds a Doctor of Philosophy from The University of Hull (1991), specializing in Emulsion stability and breakdown. His research focuses on biological physics, biomaterials, biointerfaces, and peptide self-assembly, with a strong emphasis on antimicrobial peptides, nanostructure fabrication, and neutron scattering techniques. Key projects include investigations into structural changes of antibody molecules at interfaces, development of novel biocides against antimicrobial resistance, and contributions to the Manchester Bioelectronics Network. Lu has supervised 33 research students and led/co-led projects totaling £2.5M in funding. His work spans UN Sustainable Development Goals related to health and environmental sustainability. Research highlights include enzyme-triggered drug delivery systems, surfactant-pesticide interactions, and pH-responsive peptide gels. His lab employs advanced techniques like neutron reflectivity and molecular dynamics simulations to study protein-surface interactions and antimicrobial mechanisms. Lu's recent work explores biocompatible nanomaterials for medical applications and sustainable water purification using bioinspired materials.

پروفایل رسمی دانشگاه

Mandana Arbabمشاهده پروفایل

استادیار

Boston Children's HospitalUnited States

Mandana Arbab is the Lodish Family Assistant Professor of Neurology at Harvard Medical School and faculty member of the Rosamund Stone Zander Translational Neuroscience Center at Boston Children's Hospital. Her research program focuses on developing precision gene editing therapies for neurodegenerative disorders. Current work employs CRISPR-based technologies to correct genetic mutations underlying conditions like spinal muscular atrophy and telomere biology disorders. Recent publications demonstrate innovations in base editing systems, including engineering novel editors with reduced off-target effects. Her 2023 Science paper established preclinical proof-of-concept for base editing in spinal muscular atrophy. Dr. Arbab's lab combines high-throughput screening, machine learning, and molecular biology to optimize therapeutic genome editing. She was awarded the NIH Pathway to Independence Award for her work advancing neurological gene therapies.

پروفایل رسمی دانشگاه

Xianghong Jasmine Zhouمشاهده پروفایل

استاد

University of California, Los AngelesUnited States

Dr. Xianghong Jasmine Zhou is a Professor in the Department of Pathology and Laboratory Medicine at the University of California, Los Angeles (UCLA) School of Medicine . Her work focuses on integrating genomic , epigenetic , and bioinformatic approaches for non-invasive cancer detection and monitoring through cell-free DNA analysis . Principal Investigator for multiple NIH grants (R01CA246329, U01CA230705, etc.) Developed software tools ( cfSNV , cfTools , CancerDetector ) for cell-free DNA mutation and methylation analysis Co-developed CancerLocator and HCC EV ECG score for tumor-of-origin prediction and hepatocellular carcinoma monitoring Research Interests: Specializes in 3D genome modeling , epigenetic regulation , and machine learning for liquid biopsy applications. Her work bridges computational biology with clinical translation , particularly in cancer diagnostics and treatment response assessment . Scientific Contributions: She has pioneered deep learning and population-based modeling approaches for cell-free DNA deconvolution , isoform-level functional annotation , and multi-omics integration . Her 2016 Cell paper on alternative splicing has been highly influential, with over 266 mentions.

پروفایل رسمی دانشگاه

Sarah Cartmellمشاهده پروفایل

استاد

The University of ManchesterUnited Kingdom

Sarah Cartmell is a Professor of Bioengineering and Head of the Department of Materials at The University of Manchester. She holds senior roles in the School of Natural Sciences, including Senate membership and leadership in advanced materials initiatives like the Royce Institute. Her research focuses on biomaterials for regenerative medicine, including tendon repair, stem cell differentiation, and bioreactor design. Cartmell has secured over £34.7 million in grants, authored 70+ publications, and serves on editorial and review boards for journals like Science and Technology of Advanced Materials . Her work contributes to UN Sustainable Development Goals in health and innovation. Education : B.Eng (Materials Science with Clinical Engineering, University of Liverpool, 1996), Ph.D. (Clinical Engineering, University of Liverpool, 2000), Postdoc at GeorgiaTech, and academic roles at Keele University. Research Interests : Translation of novel tissue repair products, mechanical force effects on stem cells, and advanced biomaterials for bone and cartilage regeneration. Grants & Funding : £12.7M as lead PI and £22M as PI/Co-I across 22 sources (government, industry, charities). Awards : President of UK Tissue and Cell Engineering Society, IOM3 Fellow, and TERMIS EU council member. Leadership : Led the Royce Institute’s biomedical materials initiative, coordinating 200+ stakeholders, and chairs major international conferences in biomaterials and tissue engineering. Projects : Includes AMFaces (3D-printed facial prosthetics), biomaterials for regenerative medicine, and bioelectronics networks. Labs/Teams : Biomaterials Research Group, Manchester Bioelectronics Network, and advanced materials in medicine initiatives. Her research bridges clinical and industrial applications, emphasizing translational solutions for musculoskeletal disorders and regenerative therapies.

پروفایل رسمی دانشگاه

Zulfiya Orynbayevaمشاهده پروفایل

استادیار

Drexel UniversityUnited States

Zulfiya Orynbayeva, PhD, is an Assistant Professor in the Department of Surgery at Drexel University College of Medicine. Her research focuses on mitochondria pathophysiology and nanomedicine, particularly investigating energy metabolism in cancer, neurodegeneration, and reproductive system pathologies. Education: MSc and PhD in Biophysics from Tashkent State University (1984-1993). Research Interests : - Mitochondrial dysregulation in tumors and its role in metabolic adaptation - Development of anti-cancer therapies targeting mitochondrial energy pathways - Oocyte competence and mitochondrial energy requirements - Single-cell array nanotechnologies for metabolic analysis Techniques : Oxygraph-2K for mitochondrial screening, optical spectroscopy, amperometric methods, and nanoscale probes. Patent : A method and apparatus for measuring biological activity with single-cell resolution (US10253289, 2015). Contact: zulfiya.orynbayeva@drexelmed.edu | Department of Surgery, Drexel University College of Medicine.

پروفایل رسمی دانشگاه

Jose M Silvaمشاهده پروفایل

استاد

Icahn School of Medicine at Mount SinaiUnited States

Jose M Silva is a Professor in Pathology and Oncological Sciences at Columbia University Medical School. He holds adjunct faculty status and has prior roles including Assistant Professor at Columbia and postdoctoral training at Cold Spring Harbor Laboratory. His research focuses on cancer genomics, functional networks, and translating discoveries into clinical applications. He has pioneered integrative approaches combining genomics and systems biology to identify critical cancer cell regulators, leading to clinical trials. Education: BSc, Complutense University of Madrid PhD, Autonoma University of Madrid PostDoc & Senior Fellow, Cold Spring Harbor Laboratory Research Interests: His lab investigates breast cancer development and therapeutics, including molecular characterization of tumor networks, novel drug targets (e.g., RSF1, BIN3), and clinical translation of discoveries. Current efforts target triple-negative breast cancers and aging-cancer intersections. Grants & Trials: Initiated NCT02066532 clinical trial; ongoing work includes HDAC6/STAT3 inhibition studies and single-cell atlas projects.

پروفایل رسمی دانشگاه

Sven Hermannمشاهده پروفایل

مدرس ارشد

University of MünsterGermany

Sven Hermann is a Senior Lecturer at the European Institute for Molecular Imaging (EIMI) within the University of Münster, leading the Preclinical Imaging Group. His research focuses on developing molecular imaging strategies for inflammation and infection, including PET, SPECT, fluorescence reflectance imaging, and optoacoustic imaging. Key targets include matrix metalloproteinases (MMPs) and alarmins (S100A8/S100A9), with applications in cardiovascular diseases, rheumatoid arthritis, and bacterial imaging. He participates in the Cells in Motion Cluster of Excellence and leads DFG-funded projects TRR332-C07 and CRC1450-C03, investigating immune regulation and imaging techniques. Affiliations: EIMI, University of Münster; Core Unit Pix (preclinical imaging). Research Themes: Bacterial imaging via maltodextrin transporters, MMP activity visualization in atherosclerosis, and S100A8/A9-driven immune modulation. His work integrates engineering and biology to translate imaging innovations into clinical applications, emphasizing multimodal approaches for disease monitoring.

پروفایل رسمی دانشگاه

Vivek Guptaمشاهده پروفایل

دانشیار

St. John's UniversityUnited States

Dr. Vivek Gupta is an Associate Professor of Pharmaceutical Sciences at St. John’s University’s College of Pharmacy and Health Sciences. His research focuses on non-invasive drug delivery systems, nanotherapeutics, and therapies for rare respiratory diseases. He leads a lab developing scalable technologies for pulmonary and nasal drug delivery, with contributions to rare disease research and clinical translation. PhD in Pharmaceutical Sciences from Texas Tech University (2010) BS in Pharmaceutical Sciences from Jamia Hamdard (2003) Postdoctoral training in Chemical Engineering at UC Santa Barbara (2011–2013) Dr. Gupta’s research interests include inhalation drug delivery, rare diseases (e.g., mesothelioma, pulmonary hypertension), and drug repurposing. His lab has published over 115 peer-reviewed articles and holds multiple licensed technologies. Current projects involve nanomedicine manufacturing using high-pressure homogenizers and in-situ gels for localized delivery. Articles focus on nanocarriers for lung cancer, pulmonary fibrosis, and glioblastoma treatment. Recent work highlights scalable techniques like high-pressure homogenization and QbD approaches for formulation optimization. His lab also explores excipient roles in inhaled dosage forms. Recipient of grants from the American Heart Association and PulmoSIM Therapeutics Mentor for graduate students (e.g., Mural Quadros, Meghana Mokashi) and postdoctoral fellows Led the development of the Gupta Lab, which collaborates across disciplines to address unmet needs in respiratory and oncological diseases. Current lab activities include pulmonary hypertension therapies and AI-driven drug discovery via partnerships with VeriSIM Life.

پروفایل رسمی دانشگاه

Robert Göstlمشاهده پروفایل

استاد

RWTH Aachen UniversityGermany

Prof. Robert Göstl is a Professor leading the Research Group Göstl at RWTH Aachen University, with a concurrent position as Associated Scientist at the University of Wuppertal. His research bridges synthetic organic chemistry, polymer chemistry, photophysics, and materials science, focusing on mechanoresponsive biomaterials and polymer mechanochemistry. His group investigates stress interactions with materials through innovative approaches like molecular fractography and force-induced bond scission. Key research areas include: Development of optical force probes for polymer damage analysis Ultrasound-activated therapeutic release systems Mechanochemical activation of biomolecules Design of stimuli-responsive hydrogels and microgels Analyses of recent publications show strong emphasis on ultrasound-mediated drug delivery (40% of recent works), advanced polymer characterization techniques (25%), and biomaterial applications (35%). Primary methodologies include mechanophore design, super-resolution microscopy, and nanoparticle-polymer composites. Prof. Göstl currently supervises six PhD students working on projects including: Microgel-cell interactions Nanoscale fractography of composites Force-induced reaction pathways Thermally stable optical probes His laboratory develops experimental platforms for polymer mechanochemistry including specialized synthesis routes, confocal microscopy setups, and ultrasound application systems for material testing.

پروفایل رسمی دانشگاه

Karuna Ganeshمشاهده پروفایل

استادیار

Memorial Sloan Kettering Cancer CenterUnited States

Karuna Ganesh, MD, PhD is an Assistant Professor and Medical Oncologist at Memorial Sloan Kettering Cancer Center (MSKCC). Her research focuses on understanding molecular mechanisms driving metastasis in colorectal cancer, particularly regenerative plasticity and metastasis stem cells (MetScs). She leads the Karuna Ganesh Lab within the Molecular Pharmacology Program, utilizing patient-derived organoids, mouse models, and single-cell technologies to study therapy resistance and metastasis. Dr. Ganesh completed her MD/PhD at the University of Cambridge, followed by residency at Beth Israel Deaconess Medical Center and fellowship at MSKCC. Her lab investigates four core areas: 1) phenotypic plasticity during metastasis; 2) stromal-immune interactions; 3) therapeutic target identification; and 4) clinical translation through collaborations. Key achievements include developing an organoid platform for personalized chemoradiation testing, discovering L1CAM's role in metastasis initiation, and defining progressive plasticity pathways in metastatic progression. Dr. Ganesh's awards span 2004-2024 including the Gates Cambridge Scholarship, NIH MERIT Award, and Pershing Square Sohn Prize. She holds affiliations with the Center for Stem Cell Biology, Alan & Sandra Gerry Metastasis Center, and Gerstner Sloan Kettering Graduate School. Current lab members include 14 researchers across postdocs, technicians, and students working on computational biology, experimental oncology, and translational research.

پروفایل رسمی دانشگاه

Ingo Mellinghoffمشاهده پروفایل

استاد

Memorial Sloan Kettering Cancer CenterUnited States

Ingo K. Mellinghoff is a physician-scientist and Professor at Memorial Sloan Kettering Cancer Center (MSKCC), serving as Chair of the Department of Neurology. He leads the Human Oncology & Pathogenesis Program (HOPP) laboratory, focusing on molecular mechanisms of brain tumor growth, particularly gliomas and primary CNS lymphomas. His work bridges experimental models and clinical trials, emphasizing targeted therapies and liquid biopsy applications. Affiliations: Brain Tumor Center, Gerstner Sloan Kettering Graduate School Research interests include IDH mutations, tumor metabolism, microenvironment interactions, and biomarker-driven trials. Notable achievements include advancing vorasidenib (a mutant IDH inhibitor) to phase 3 trials and developing cerebrospinal fluid-based liquid biopsy techniques for glioma monitoring. Recent articles highlight clinical trial results for IDH inhibitors and translational studies on tumor biology. Awards include the Neuro-Oncology Scientific Award (2023) and membership in prestigious medical societies.

پروفایل رسمی دانشگاه

Daniel Bachovchinمشاهده پروفایل

استاد

Memorial Sloan Kettering Cancer CenterUnited States

Dr. Daniel Bachovchin is a Professor and Geoffrey Beene Junior Faculty Chair at Memorial Sloan Kettering Cancer Center's Sloan Kettering Institute, leading the Chemical Biology Program. He holds faculty roles at Weill Cornell Medical College, Rockefeller University, and Gerstner Sloan Kettering Graduate School. His research focuses on enzyme functions in cancer and immunity, particularly serine proteases' roles in inflammasome activation. He earned his PhD from The Scripps Research Institute and AB from Harvard University. Expertise: Innate immunity, inflammasome biology, protease inhibition, chemical probes Affiliations: Tri-Institutional Chemical Biology Program, Pharmacology training programs Key research themes include NLRP1 and CARD8 inflammasome mechanisms, redox signaling, and pyroptosis pathways. His lab develops small molecule inhibitors and activity-based probes to study these systems. Recent work highlights include discovering DPP8/9 inhibitors as pyroptosis inducers in cancer and uncovering redox stress sensing by inflammasomes. Over 90 peer-reviewed publications span high-impact journals like Science , Nature , and Cell . Awarded multiple grants including Pershing Square Sohn Prize, Sloan Fellowship, and teaching awards. Mentors over 20 trainees, including PhD students and postdocs in chemical biology and immunology.

پروفایل رسمی دانشگاه

نمایش نتایج تا ۷۵۰ مورد اول. برای یافتن نتایج دقیق‌تر، جستجوی خود را با فیلترها محدود کنید.